CLINICAL TRIAL TO EFFICACY OF INJI CHOORANAM - 2 [INTERNAL], VATHA KESARI THYLAM [EXTERNAL] AND VARMA THADAVAL [EXTERNAL THERAPY] in HEMIPLEGIA.
- Conditions
- Health Condition 1: null- Patients suffering from Hemiplegia
- Registration Number
- CTRI/2018/05/013699
- Lead Sponsor
- Mathan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
2.SEX: Both male and female.
3. Inability/ difficulty to use one side of the upper and lower limb.
4. Difficulty in speech.
5.Patient with Thrombotic or Embolic stroke.
6.Willing for admission in IPD for 48 days or willing to attend OPD regularly.
7.Patients who are willing to participate in this study with knowledge of potential risks and who are willing to sign the informed consent form.
8.Patient who are willing to give blood sample for laboratory investigation
1.Patient in an acute phase of CVA.
2.Pregnant women and lactating mother.
3.Known Hypersensitivity or allergy to trial drugs.
4.Patients with other serious, advanced or terminal illness.
5.Bed sores.
6.Bladder and Bowel control lost.
7.Epilepsy.
8.Comatose and unconscious patients.
9.Patient with haemorrhagic stroke, Neoplasam, subarachanoid haemorrhage, AV malformation.
10.Dermatological issues.
11.Congenital defects -diffuse sclerosis, cerebral agenesis etc.
12.Post operative cases within 3 months [eg.CVD, etc.], Head injury.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome will be assessed based on assessment criteria for stroke patientsTimepoint: 48 days
- Secondary Outcome Measures
Name Time Method Assessment of quality of life with respect to SS-QOL. <br/ ><br>2.Assessment of improvement in clinical signs and symptoms with respect to following of Iyama and Niyama. <br/ ><br>3.To evaluate the clinical efficacy of the trial drug with respect to theganilai. <br/ ><br> <br/ ><br>Timepoint: 48 days